News and Events, Recent News

BriaCell Presents Positive Efficacy Data with Lead Cancer Drug Candidate in Phase IIa Monotherapy and Excellent Initial Safety Data in Combination with KEYTRUDA® at a Major Breast Cancer Conference

· Interim data indicate an excellent safety profile for the combination regimen in advanced breast cancer patients. Initial efficacy data is expected in first quarter of 2019; · Confirmed positive proof-of-concept with Bria-IMT™ Monotherapy demonstrates promising anti-tumor activity with excellent safety and tolerability in advanced breast cancer patients. BERKELEY, Calif., and VANCOUVER, British Columbia, December […]

News and Events, Recent News

UPDATED – BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium

Note: This Press Release contains amendments to the press release previously issued on Nov. 19, 2018 · Positive proof of concept data with Bria-IMT™ Monotherapy will highlight potent anti-tumor activity and an excellent safety profile for Bria-IMT™ in advanced breast cancer. · Patient dosing is ongoing in a combination study of Bria-IMT™ with KEYTRUDA® (by […]

News and Events, Recent News

BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium

· Positive proof of concept data with Bria-IMT™ Monotherapy will highlight potent anti-tumor activity and an excellent safety profile for Bria-IMT™ in advanced breast cancer. · Patient dosing is ongoing in a combination study of Bria-IMT™ with KEYTRUDA® (by Merck & Co., Inc.) in advanced breast cancer. · Interim safety data of the combination study […]

News and Events, Recent Events

BriaCell Therapeutics Corp.’s CEO Talks Personalized Breast Cancer Treatment Technology with Uptick Newswire’s Stock Day Podcast

Phoenix, Nov. 6, 2018 (GLOBE NEWSWIRE) – BriaCell Therapeutics Corp. (“BriaCell,” the “Company”) (TSX-V: BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that Dr. Bill Williams, BriaCell’s president and CEO, was recently interviewed by Everett Jolly of Stock Day. “BriaCell is developing the first off-the-shelf, personalized […]

News and Events, Recent News

BriaCell Initiates Dosing in Phase I/IIa Combination Study with KEYTRUDA® or YERVOY®

· Patient dosing is underway in a combination study of Bria-IMT™ with KEYTRUDA® (by Merck & Co., Inc.) or YERVOY® (by Bristol-Myers Squibb Company) in advanced breast cancer. · KEYTRUDA® and YERVOY® have been highly recognized for their potent immune boosting properties – Nobel Prize in Medicine 2018 – validating BriaCell’s strategy to use these […]

News and Events, Recent News

BriaCell Announces Positive Phase IIa Proof of Concept Data in Advanced Breast Cancer; Initiates Combination Study

· BriaCell has achieved positive proof of concept in the Phase IIa study of Bria-IMT™ in advanced breast cancer patients · Data shows promising anti-tumor activity of Bria-IMT™ in heavily pre-treated advanced breast cancer patients · Impressive Phase IIa efficacy data is similar or superior to those of other approved breast cancer drugs of similar […]

News and Events, Recent Events

BriaCell Therapeutics Corp. Discusses its Plan to Revolutionize Cancer Immunotherapy in Exclusive NetworkNewsWire Audio Interview

NEW YORK (Sept 25, 2018) – via NetworkWire – NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community, today announces the online availability of its interview with BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT) (“BriaCell” or “the Company”), focused on developing a targeted and safe […]

News and Events, Recent Events

Coverage Initiated for BriaCell Therapeutics Corp. via NetworkNewsWire

NEW YORK, Sept. 21, 2018 (GLOBE NEWSWIRE) — via NetworkWire – BriaCell Therapeutics Corp. (OTCQB: BCTXF; TSX: BCT.V) (BriaCell or the Company), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announces that it has selected NetworkNewsWire (“NNW”) to assist the Company with its corporate communications initiatives. BriaCell is currently developing a targeted […]

News and Events, Recent News

BriaCell to Present Clinical and Scientific Data at International Cancer Immunotherapy and The MicroCap Conferences

– Scientific findings will discuss circulating tumor cells as a biomarker of tumor response, which is key to the advancement of BriaCell’s BriaDX™, a diagnostic test designed to determine which patients are most likely to respond to treatment. – Phase I/IIa clinical efficacy data will be announced in advance of these conferences. (Accesswire — September […]

News and Events, Recent Events

Dr. William Williams, BriaCell’s President & CEO, is Featured in an Exclusive New Audio Interview at SmallCapVoice.com

AUSTIN, Texas—8/28/18– SmallCapVoice.com, Inc. and BriaCell Therapeutics Corp. (“BriaCell”) (BCT.V) (BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that the Company’s President & CEO, Dr. William Williams, is featured in a new audio interview at SmallCapVoice.com, Inc. The new Bricell interview can be heard at https://smallcapvoice.com/blog/8-27-18-smallcapvoice-interview-with-briacell-therapeutics-corp-bctxf/. Dr. Williams, BriaCell’s […]